Danaher (NYSE:DHR)‘s stock had its “hold” rating reiterated by research analysts at Royal Bank of Canada in a research report issued to clients and investors on Thursday, January 4th. They presently have a $96.00 price objective on the conglomerate’s stock. Royal Bank of Canada’s target price would suggest a potential downside of 4.53% from the stock’s previous close.

Other research analysts have also issued research reports about the company. Robert W. Baird reiterated a “buy” rating and issued a $99.00 target price on shares of Danaher in a research report on Friday, December 15th. Citigroup boosted their price objective on Danaher to $107.00 and gave the company a “buy” rating in a research report on Friday, December 15th. Zacks Investment Research upgraded Danaher from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research report on Thursday, October 5th. Cowen reaffirmed a “buy” rating and set a $90.00 target price on shares of Danaher in a research note on Wednesday, October 4th. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $99.00 target price on shares of Danaher in a research note on Tuesday, December 19th. One analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $95.86.

Danaher (DHR) opened at $100.56 on Thursday. The company has a market capitalization of $69,950.05, a P/E ratio of 29.66, a PEG ratio of 2.18 and a beta of 1.02. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.00. Danaher has a 12-month low of $78.97 and a 12-month high of $100.88.

In other Danaher news, CEO Thomas Patrick Joyce, Jr. sold 125,989 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $92.64, for a total value of $11,671,620.96. Following the transaction, the chief executive officer now owns 271,737 shares in the company, valued at $25,173,715.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Donald J. Ehrlich sold 10,578 shares of the company’s stock in a transaction dated Tuesday, October 24th. The stock was sold at an average price of $90.82, for a total value of $960,693.96. Following the sale, the director now owns 104,621 shares of the company’s stock, valued at approximately $9,501,679.22. The disclosure for this sale can be found here. Insiders have sold 174,437 shares of company stock worth $16,166,722 in the last quarter. 12.20% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GQG Partners LLC acquired a new position in shares of Danaher during the 2nd quarter worth about $101,000. Zions Bancorporation lifted its position in shares of Danaher by 118.3% during the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after purchasing an additional 667 shares during the last quarter. Monetary Management Group Inc. lifted its position in shares of Danaher by 10.7% during the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after purchasing an additional 150 shares during the last quarter. Acrospire Investment Management LLC lifted its position in shares of Danaher by 185.5% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,693 shares of the conglomerate’s stock worth $143,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Motco lifted its position in shares of Danaher by 8.8% during the 2nd quarter. Motco now owns 2,011 shares of the conglomerate’s stock worth $170,000 after purchasing an additional 163 shares during the last quarter. Institutional investors own 76.12% of the company’s stock.

WARNING: “Danaher’s (NYSE:DHR) Hold Rating Reiterated at Royal Bank of Canada” was posted by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.mareainformativa.com/danaher-dhr-earns-hold-rating-from-royal-bank-of-canada-updated-updated/125875/.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.